Compare Quest Diagnostics Inc (DGX) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Quantumscape Corp — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Quantumscape Corp trades at $4.67 (market cap $2.78B). The key difference: Quest Diagnostics Inc is far larger — about 9× Quantumscape Corp's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Quantumscape Corp for 37 Days on average.
| DGX | QS | |
|---|---|---|
Market Cap | $25.06B | $2.78B |
Volume | 927,361 | 11,236,221 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $18.44 |
52-Week Low | $173.49 | $4.52 |
Typical Hold Time | 56 Days | 37 Days |
Enterprise Value | $30.82B | $1.99B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
QuantumScape (QS) trades at $4.52, down 2.8% today, reflecting ongoing investor skepticism about the solid-state battery developer's commercial timeline. The company remains pre-revenue with negative $435M net income in 2025, though it has beaten EPS estimates in two of the last three quarters. Technical indicators show bearish momentum with the stock trading near key support levels, while analyst sentiment remains cautious with 73% hold ratings.
QS faces significant execution risk with commercialization not expected until 2029, creating substantial uncertainty for investors. The stock trades at a discount to the $10.35 consensus target, offering potential upside if technology milestones are met, but requires high risk tolerance given the lengthy path to profitability and intense competition in battery technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
